Lundin J, Lehtimäki T, Lundin M, Holli K, Elomaa L, Turpeenniemi-Hujanen T, Kataja V, Isola J, Joensuu H. Generalizability of survival estimates for patients with breast cancer - a comparison across two population-based series. Eur J Cancer 2006;42:3228-35.

Joensuu H, Lehtimaki T, Holli K, Elomaa L, Turpeenniemi-Hujanen T, Kataja V, Anttila A, Lundin M, Isola J, Lundin J. Risk for distant recurrence of breast cancer detected by mammography screening or other methods.
JAMA. 2004 Sep 1;292(9):1064-73.

Linder N, Lundin J, Isola J, Lundin M, Raivio KO, Joensuu H. Down-regulated xanthine oxidoreductase is a feature of aggressive breast cancer. Clin Cancer Res 2005;11(12):4372-81.

Junttila T, Sundvall M, Lundin M, Lundin J, Tanner M, Härkönen P, Joensuu H, Isola J, Elenius K. Cleavable ErbB4 isoforms in prognosis and estrogen-regulated growth of breast cancer. Cancer Research 2005 Feb 15;65(4):1384-93

Zhang F, Lundin M, Ristimäki A, Heikkilä P, Lundin J, Isola J, Joensuu H, Laiho M. Ski-related novel protein N (SnoN), a negative controller of transforming growth factor-beta signaling, is a prognostic marker in estrogen receptor-positive breast carcinomas. Cancer Res 2003;63:5005-5010.

Lundin J, Lundin M, Isola J, Joensuu H. A web-based system for individualized survival estimation in breast cancer. BMJ 2003;326:29.

Joensuu H, Isola J, Lundin M, Holli K, Kataja V, Pylkkänen L, Turpeenniemi-Hujanen T, von Smitten K, Lundin J. Amplification of erbB2 and erbB2 expression are superior to estrogen receptor status as risk factors for distant recurrence in pT1N0M0 breast cancer: A nationwide population-based study. Clin Cancer Res 2003;9:923-930.

Ristimaki A, Sivula A, Lundin J, Lundin M, Salminen T, Haglund C, et al. Prognostic significance of elevated cyclooxygenase-2 expression in breast cancer. Cancer Res 2002;62(3):632-5.

Lundin J, Lundin M, Holli K, Kataja V, Elomaa L, Pylkkanen L, et al. Omission of histologic grading from clinical decision making may result in overuse of adjuvant therapies in breast cancer: results from a nationwide study. J Clin Oncol 2001;19(1):28-36.

Rummukainen JK, Salminen T, Lundin J, Joensuu H, Isola JJ. Amplification of c-myc oncogene by chromogenic and fluorescence in situ hybridization in archival breast cancer tissue array samples. Lab Invest 2001;81(11):1545-51.

Rummukainen JK, Salminen T, Lundin J, Kytola S, Joensuu H, Isola JJ. Amplification of c-myc by fluorescence in situ hybridization in a population-based breast cancer tissue array. Mod Pathol 2001;14(10):1030-5.

Lundin M, Lundin J, Burke HB, Toikkanen S, Pylkkanen L, Joensuu H. Artificial neural networks applied to survival prediction in breast cancer. Oncology 1999;57(4):281-6.